Join us in March as we raise awareness about colorectal cancer. Even the most proactive patients and advocates can only act on what they know. Help us spread the word about colorectal cancer!
Colorectal cancer is the third most common cancer and also the third leading cause of cancer-related deaths in the United States; however, survival has consistently improved over the last several decades. This is largely due to screening with routine colonoscopy, which provides visualization of the entire colon allowing biopsies of polyps or areas of concern. Routine colonoscopies are recommended every 10 years, beginning at age 45 through 75 years. Recently, the rates of colon cancers in younger populations (under 55 years of age) in the United States have been rising, prompting routine colonoscopies to be recommended in even younger patients who may be at higher risk.
The survival rates for colorectal cancer vary greatly depending on the stage of disease at the time of diagnosis. The five-year survival rate for stage I colon cancer is 92%, but dramatically decreases to 12% for stage IV disease.
Key Facts
Younger Diagnosis: An increasing number of patients are being diagnosed at a younger age and with more advanced colorectal cancer, which poses a significant clinical challenge
Chemotherapy: Systemic chemotherapy alone has limited efficacy in advanced and metastatic colorectal cancer, reserving it for palliative treatment
Multimodal Treatment: The treatment of choice for advanced colorectal cancer is a multimodal approach, including cytoreductive surgery and systemic chemotherapy. The best survival is achieved with a complete cytoreduction and patients with a lower disease burden experience the greatest survival benefit
CRS/HIPEC: The role of HIPEC at the time of cytoreductive surgery continues to evolve. Current evidence suggests that complete CRS/HIPEC with mitomycin-C is associated with improved abdominal disease control
Join us
Come visit us on social media to follow along during the month of March to learn more about colorectal cancer and help spread the word!
follow us on Facebook here:  | follow us on LinkedIn here:  |
